Frequency of molecular subtypes of breast cancer, Hospital Metropolitano, 2016-2019, Quito- Ecuador
DOI:
https://doi.org/10.47464/MetroCiencia/vol28/3/2020/32-38Keywords:
Breast cancer, Molecular subtypes, ImmunohistochemistryAbstract
Objective: To determine the most common molecular type of breast cancer in the Hospital Metropolitano. Methodology: This was a retrospective descriptive study, in which the histopathological reports of all breast cancer cases diagnosed from January 1, 2016 to December 31, 2019 were reviewed, taking into account immunohistochemical data for classification. In the period studied, a total of 276 cases corresponding to breast cancer were evidenced, after classifying individual criterias, data from 147 patients were analyzed. Results: The annual average of new cases was 40 ± 6. The average age at diagnosis was 60.9 ± 13 years. A large number of patients are in the age range of 40 to 69 years with 101 cases (69%). More than a half were Luminal B type with a total of 85 cases which corresponds to 54%, the minority were triple negative type with 11 cases (7%). The predominant number of cases (71%) have high tumor profiling determined by Ki-67. Conclusions: In this retrospective study we found that the most common molecular subtype of breast cancer is Luminal B, and the least frequent is triple negative. The results also demonstrate that most of the cases have high proliferation determined the value of Ki-67.
Downloads
References
Wyld L, Markopoulos C. Breast Cancer Management for Surgeons. Breast Cancer Management for Surgeons. Cham: Springer International Publishing AG; 2018.
GLOBOCAN-WHO. Cancer Today [Internet]. International Agency for research. 2018 [cited 2019 Nov 12]. Available from: https://gco.iarc.fr/today/online-analysis-dual-bars-2?v=2018&mode=cancer&mode_population=regions&population=250&populations=250&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=10&g
Viana Zulaica C. Cáncer de mama [Internet]. FISTERRA. 2018. Available from: https://www.clinicalkey.es/#!/content/guides_techniques/52-s2.0-mt_fis_49
Ministerio de Salud Pública del Ecuador. Cifras de Ecuador : Cáncer de Mama [Internet]. Cifras De Ecuador. 2018 [cited 2019 Sep 13]. Available from: https://www.salud.gob.ec/cifras-de-ecuador-cancer-de-mama/
Kumar N, Patni P, Agarwal A, Khan MA, Parashar N. Prevalence of molecular subtypes of invasive breast cancer: A retrospective study. Med J Armed Forces India. 2015;71(3):254–8.
Breastcancer.org. Risk of Developing Breast Cancer [Internet]. 2016 [cited 2019 Nov 21]. Available from: https://www.breastcancer.org/symptoms/understand_bc/risk/understanding
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Vol. 144, Cell. 2011. p. 646–74.
Eliyatkin N, Yalcin E, Zengel B, Aktaş S, Vardar E. Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. J Breast Heal. 2015 Apr 7;11(2):59–66.
Emory University. Inmunohistoquímica (IHC) | CancerQuest [Internet]. [cited 2019 Nov 16]. Available from: https://www.cancerquest.org/es/para-los-pacientes/deteccion-y-diagnosis/inmunohistoquimica
O’toole SA, Selinger CI, Millar EKA, Lum T, Beith JM. Molecular assays in breast cancerpathology. Royal College of pathologists of Australasia. 2011;43(2):116–27.
Cuzick J, Dowsett M, Wale C, Salter J, Quinn E, Zabaglo L, et al. Prognostic Value of a Combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and Comparison with the GHI Recurrence Score – Results from TransATAC. Cancer Res [Internet]. 2009 Dec 15 [cited 2020 Aug 20];69(24 Supplement):74–74. Available from: https://sci-hub.st/https://cancerres.aacrjournals.org/content/69/24_Supplement/74
Navarro JM, Castro CS. Inmunohistoquímica en el cáncer de mama. Herramienta necesaria en la actualidad. Medisur [Internet]. 2018 [cited 2019 Nov 21];209–13. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1727-897X2018000100016
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: American society of clinical oncology/college of American pathologists guideline update. Arch Pathol Lab Med [Internet]. 2020 May 1 [cited 2020 Aug 20];144(5):545–63. Available from: http://meridian.allenpress.com/aplm/article/144/5/545/427509/Estrogen-and-Progesterone-Receptor-Testing-in
Enzo Life Sciences. Immunohistochemistry E-Book. 2018.
Almarzooq R, Alrayes A, Alaradi H, Abdulla H. Molecular subtypes of breast cancer. Bahrain Med Bull [Internet]. 2018 [cited 2019 Sep 14];40(4):222–5. Available from: https://www.breastcancer.org/symptoms/types/molecular-subtypes
MacKay A, Weigelt B, Grigoriadis A, Kreike B, Natrajan R, A’Hern R, et al. Microarray-based class discovery for molecular classification of breast cancer: Analysis of interobserver agreement. J Natl Cancer Inst. 2011 Apr 20;103(8):662–73.
Fitzgibbons PL, Bartley AN, Connolly JL. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast. Coll Am Pathol. 2020;4(February):1–15.
Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med. 2016;13(4):496–504.
Cáceres V. Tratamiento sistémico: Adyuvancia, parámetros de evaluación para su indicación y utilidad de las firmas genéticas. In: Diagnóstico y tratamiento del cáncer de mama Guía de procedimientos. 1ra ed. Ciudad Autónoma de Buenos Aires; 2016. p. 87–98.
Chand P, Anubha G, Singla V, Rani N. Evaluation of immunohistochemical profile of breast cancer for prognostics and therapeutic use. Niger J Surg. 2018;24(2):100.
Zaha DC. Significance of immunohistochemistry in breast cancer. Vol. 5, World Journal of Clinical Oncology. Baishideng Publishing Group Co., Limited; 2014. p. 382–92.
Witten MO, Krontiras H, Bland FACS KI, Lancaster RB. Molecular Targets in Breast Cancer. In: Current Surgical Therapy. 2020. p. 670–675.
Bhargava R. Molecular Classification of Breast Carcinoma. In: Breast Pathology. Second Edi. Elsevier Inc.; 2017. p. 417–35.
Cleator S, Ashworth A. Molecular profiling of breast cancer: Clinical implications. Vol. 90, British Journal of Cancer. 2004. p. 1120–4.
Schmid P. Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer. What Should You Know? In London: Medscape Education; 2019. Available from: https://www.medscape.org/viewarticle/920637_2
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Daniela Vela Merino, Stephania Salazar Chiriboga, Danilo Salazar Molina
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
